Clinical Trial Update: The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating the immunology and safety of maternal RSV vaccination ABRYSVO and infant nirsevimab BEYFORTUS, alone or in combination.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• ABRYSVO
• BEYFORTUS (Nirsevimab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Respiratory Syncytial Virus Infection | Phase 4 | Status: ACTIVE_NOT_RECRUITING